MPR1005sur : Prostatic cance and normal tissue microarray with survival data, including TNM and clinical stage, 100 cases/100 cores
  • $1,328.00
  • Unstained
  • H&E
-+
Microarray Panel Prostatic cancer and normal tissue microarray with survival data, containing 90 cases of prostatic cancer, 10 cases of normal prostatic hyperplasia tissue, single cores per case
Cores 100
TissueArray.Com Tissue Array MPR1005sur
Cases 100
Row number 10
Column number 10
Core Diameter (mm) 1.0
Thickness (µm) 5
Quality Control H&E and IHC confirmed
Tissue Array Type FFPE
Species Human
Applications Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page
Notes 1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours.
In the following specsheet,“*” means invalid core; “-” means no applicable or negative in IHC markers.
Mouseover and click individual cores to view high resolution images.
Slide Label: TissueArray.Com Tissue Array
12345678910 
AProProProProProProProProProPro 
BProProProProProProProProProPro 
CProProProProProProProProProPro 
DProProProProProProProProProPro 
EProProProProProProProProProPro 
FProProProProProProProProProPro 
GProProProProProProProProProPro 
HProProProProProProProProProPro 
IProProProProProProProProProPro 
JProProProProProProProProProProMarked point
Legend: Pro - Prostate

- Hyperplasia, - Malignant tumor, - Malignant tumor, - Malignant tumor (stage I), - Malignant tumor (stage II), - Malignant tumor (stage III), - Malignant tumor (stage IV), - NAT

Specification Sheet (Sortable), tissue IDs are available in exported Excel files.
Pos.
No.
Age
Sex
Organ/Anatomic Site
Pathology diagnosis
TNM
Grade
Stage
Type
Gleason Score
Gleason Grade
survival status
Image
A1
1
67
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+3=6
1
Survival,57 mo
A2
2
72
M
Prostate
Prostate cancer (prostatectomy)
T2cN0M0
II
Malignant
3+3=6
1
Survival,33 mo
A3
3
65
M
Prostate
Prostate cancer
T2aN0M0
I
Malignant
3+3=6
1
Survival,21 mo
A4
4
73
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+3=6
1
Deceased,51mo (died of CVD)
A5
5
63
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+4=7
2
Survival,57 mo
A6
6
75
M
Prostate
Prostate cancr (fibrous tissue)
T2aN0M0
I
Malignant
-
-
Survival,39 mo
A7
7
73
M
Prostate
Prostate cancer (prostatectomy)
-
-
Malignant
3+3=6
1
Survival,39 mo
A8
8
68
M
Prostate
Prostate cancer
T2aN0M0
I
Malignant
3+3=6
1
Survival,54 mo
A9
9
83
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+3=6
1
Survival,18 mo
A10
10
72
M
Prostate
Prostatic hyperplasia
T2bN0M0
II
Malignant
-
-
Survival,36 mo
B1
11
71
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+3=6
1
Survival,24 mo
B2
12
79
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
4+4=8
4
Survival,33 mo
B3
13
66
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+3=6
1
Survival,42 mo
B4
14
69
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+4=7
2
Deceased,63 mo
B5
15
67
M
Prostate
Prostate cancer (prostatectomy)
T2aN0M0
I
Malignant
3+3=6
1
Survival,45 mo
B6
16
65
M
Prostate
Prostate cancer
T2aN0M0
I
Malignant
4+3=7
3
Survival,57 mo
B7
17
82
M
Prostate
Prostate cancer
-
-
Malignant
3+4=7
2
Deceased,63 mo
B8
18
74
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+4=7
2
Survival,30 mo
B9
19
74
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
4+3=7
3
Deceased,66 mo
B10
20
58
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+4=7
2
Survival,24 mo
C1
21
76
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+4=7
2
Survival,18 mo
C2
22
68
M
Prostate
Prostate cancer
T2CN0M0
II
Malignant
4+5=9
5
Deceased,42 mo
C3
23
75
M
Prostate
Prostate cancer
T3bN0M0
III
Malignant
3+4=7
2
Survival,27 mo
C4
24
52
M
Prostate
Prostate cancer
T2cN0M0
II
Malignant
3+4=7
2
Survival,42 mo
C5
25
71
M
Prostate
Prostate cancer (sparse)
T2aN0M0
I
Malignant
5+4=9
5
Survival,39 mo
C6
26
76
M
Prostate
Prostate cancer (sparse)
T2cN0M0
II
Malignant
3+4=7
2
Survival,27 mo
C7
27
68
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
4+3=7
3
Survival,42 mo
C8
28
65
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+4=7
2
Survival,39 mo
C9
29
68
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
5+3=8
4
Survival,51 mo
C10
30
75
M
Prostate
Prostate cancer
T2aN0M0
I
Malignant
3+4=7
2
Survival,45 mo
D1
31
70
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+4=7
2
Deceased,54 mo
D2
32
81
M
Prostate
Prostate cancer
T2cNOM0
II
Malignant
3+4=7
2
Deceased,48 mo
D3
33
72
M
Prostate
Prostate cancer
T2aN0M0
I
Malignant
3+4=7
2
Survival,33 mo
D4
34
70
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
5+4=9
5
Survival,24 mo
D5
35
63
M
Prostate
Prostate cancer
T2aN0M0
I
Malignant
3+4=7
2
Survival,39 mo
D6
36
70
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+4=7
2
Survival,48 mo
D7
37
68
M
Prostate
Prostate cancer
T2cN0M0
II
Malignant
3+4=7
2
Survival,57 mo
D8
38
64
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+4=7
2
Survival,63 mo
D9
39
65
M
Prostate
Prostate cancer
T2aN0M0
I
Malignant
3+4=7
2
Survival,42 mo
D10
40
68
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+4=7
2
Deceased,57 mo
E1
41
73
M
Prostate
Prostate cancer
T2aN0M0
I
Malignant
3+4=7
2
Survival,24 mo
E2
42
62
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
4+3=7
3
Survival,18 mo
E3
43
68
M
Prostate
Prostate cancer (prostatectomy)
T2bN0M0
II
Malignant
3+4=7
2
Survival,45 mo
E4
44
72
M
Prostate
Prostate cancer
T3aN1M0
IV
Malignant
3+4=7
2
Deceased,45 mo
E5
45
71
M
Prostate
Prostate cancer
ypT2bN0m0
II
Malignant
3+4=7
2
Survival,36 mo
E6
46
75
M
Prostate
Prostate cancer
ypT3bN1M0
IV
Malignant
4+3=7
3
Deceased,66 mo
E7
47
65
M
Prostate
Prostate cancer
ypT2cN1M0
IV
Malignant
3+4=7
2
Survival,27 mo
E8
48
79
M
Prostate
Prostate cancer (prostatectomy)
-
-
Malignant
4+3=7
3
Survival,30 mo
E9
49
77
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
4+3=7
3
Survival,39 mo
E10
50
62
M
Prostate
Prostate cancer
T2aN0M0
I
Malignant
4+3=7
3
Survival,51 mo
F1
51
76
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
4+3=7
3
Survival,36 mo
F2
52
67
M
Prostate
Prostate cancer
T3bN1M0
IV
Malignant
4+3=7
3
Survival,39 mo
F3
53
66
M
Prostate
Prostate cancer
T3bN1M0
IV
Malignant
4+3=7
3
Survival,24 mo
F4
54
63
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
4+3=7
3
Survival,60 mo
F5
55
66
M
Prostate
Prostate cancer
ypT3bN1M0
IV
Malignant
4+3=7
3
Deceased,51 mo
F6
56
71
M
Prostate
Prostate cancer
ypT2bN0M0
II
Malignant
4+3=7
3
Deceased,66 mo
F7
57
79
M
Prostate
Prostate cancer (sparse)
-
-
Malignant
4+4=8
4
Deceased,36 mo
F8
58
57
M
Prostate
Prostate cancer
-
-
Malignant
4+3=7
3
Survival,36 mo
F9
59
67
M
Prostate
Prostate cancer
T2cN0M0
II
Malignant
4+4=8
4
Survival,51 mo
F10
60
70
M
Prostate
Prostate cancer
T2cN0M0
II
Malignant
3+5=8
4
Survival,15 mo
G1
61
76
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
4+4=8
4
Survival,24 mo
G2
62
72
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
5+3=8
4
Deceased,60 mo
G3
63
68
M
Prostate
Prostate cancer
-
-
Malignant
4+4=8
4
Survival,45 mo
G4
64
70
M
Prostate
Prostate cancer
T2bN0M0
II
Malignant
3+5=8
4
Survival,39 mo
G5
65
80
M
Prostate
Prostate cancer
ypT3bN1M0
IV
Malignant
4+4=8
4
Deceased,27 mo
G6
66
64
M
Prostate
Prostate cancer
ypT3bN0M0
III
Malignant
4+4=8
4
Survival,30 mo
G7
67
70
M
Prostate
Prostate cancer (fibrous adipose)
T4N0M0
III
Malignant
-
-
Survival,18 mo
G8
68
64
M
Prostate
Prostate cancer
ypT2N1M0
IV
Malignant
4+4=8
4
Survival,12 mo
G9
69
76
M
Prostate
Prostate cancer (fibrous tissue)
T3bN0M0
III
Malignant
5+4=9
5
Deceased,35 mo
G10
70
62
M
Prostate
Prostate cancer (fibrous tissue)
-
-
Malignant
-
-
Deceased,43 mo
H1
71
76
M
Prostate
Prostate cancer
-
-
Malignant
5+4=9
5
Deceased,36 mo
H2
72
70
M
Prostate
Prostate cancer
T2cN0M0
II
Malignant
5+4=9
5
Survival,45 mo
H3
73
76
M
Prostate
Prostate cancer (sparse)
T2cN0M0
II
Malignant
5+4=9
5
Survival,39 mo
H4
74
62
M
Prostate
Prostate cancer (sparse)
T2bN0M0
II
Malignant
4+5=9
5
Survival,42 mo
H5
75
68
M
Prostate
Prostate cancer
T2cN0M0
II
Malignant
5+4=9
5
Survival,27 mo
H6
76
76
M
Prostate
Prostatic hyperplasia
T2cN0M0
II
Hyperplasia
-
-
Deceased,43 mo
H7
77
66
M
Prostate
Prostate cancer
-
-
Malignant
4+4=8
4
Survival,45 mo
H8
78
62
M
Prostate
Prostate cancer
-
-
Malignant
4+5=9
5
Survival,33 mo
H9
79
63
M
Prostate
Prostate cancer
T3bN1M0
IV
Malignant
5+5=10
5
Deceased,40 mo
H10
80
59
M
Prostate
Prostate cancer
ypT2bN0M0
II
Malignant
4+5=9
5
Survival,36 mo
I1
81
72
M
Prostate
Prostate cancer
ypT4N0M0
III
Malignant
4+5=9
5
Deceased,24 mo
I2
82
60
M
Prostate
Prostate cancer
ypT3bN1M0
IV
Malignant
4+5=9
5
Survival,27 mo
I3
83
68
M
Prostate
Prostate cancer
-
-
Malignant
5+4=9
5
Survival,54 mo
I4
84
69
M
Prostate
Prostate cancer
T4N0M0
III
Malignant
4+5=9
5
Deceased,38 mo
I5
85
56
M
Prostate
Prostate cancer
TxNxM1
IV
Malignant
4+4=8
4
Deceased,40 mo
I6
86
79
M
Prostate
Prostate cancer
T4N0M0
III
Malignant
5+4=9
5
Deceased,41 mo
I7
87
64
M
Prostate
Prostate cancer
T4N0M0
III
Malignant
4+3=7
3
Survival,51 mo
I8
88
58
M
Prostate
Prostate cancer
T4N0M0
III
Malignant
5+4=9
5
Survival,45 mo
I9
89
48
M
Prostate
Prostate cancer
T4N0M0
III
Malignant
4+5=9
5
Survival,24 mo
I10
90
78
M
Prostate
Prostate cancer (sparse)
T4N0M0
III
Malignant
4+4=8
4
Deceased,41 mo
J1
91
53
M
Prostate
Benign prostatic hyperplasia with focal inflammation
-
-
NAT
-
-
-
J2
92
65
M
Prostate
Benign prostatic hyperplasia with focal inflammatory cell infiltration
-
-
NAT
-
-
-
J3
93
65
M
Prostate
Benign prostatic hyperplasia with focal inflammatory cell infiltration
-
-
NAT
-
-
-
J4
94
77
M
Prostate
Benign prostatic hyperplasia with focal inflammatory cell infiltration
-
-
NAT
-
-
-
J5
95
54
M
Prostate
Benign prostatic hyperplasia with focal inflammatory cell infiltration
-
-
NAT
-
-
-
J6
96
65
M
Prostate
Benign prostatic hyperplasia with focal inflammatory cell infiltration
-
-
NAT
-
-
-
J7
97
69
M
Prostate
Benign prostatic hyperplasia with focal inflammatory cell infiltration
-
-
NAT
-
-
-
J8
98
80
M
Prostate
Benign prostatic hyperplasia with focal inflammatory cell infiltration
-
-
NAT
-
-
-
J9
99
67
M
Prostate
Benign prostatic hyperplasia with focal inflammatory cell infiltration
-
-
NAT
-
-
-
J10
100
68
M
Prostate
Benign prostatic hyperplasia with focal inflammatory cell infiltration
-
-
NAT
-
-
-
-
0
55
F
liver
hepatocellular liver carcinoma (tissue marker)
T3N0M0
3
Malignant
Find overlapping cases with this tissue array:
 

Write a review

Please login or register to review
 
  • Product Code: MPR1005sur
  • Availability: In Stock

Tags: With normal control (), Stage (TNM), Survival data, Single core per case